Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-8554 long-term extension in postmenopausal women with vasomotor symptoms
NCT03541200Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Apr 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elismetrep in vasomotor symptoms, sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Adverse Events at 52 weeks, Serious Adverse Events at 52 weeks and 6 more. Started Apr 2018; status: completed.
02
Drugs
elismetrep
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT03541200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541200.